摘要多参数流式细胞术（MFC）在淋巴造血系统肿瘤的检测中起到至关重要的作用，但是长期以来应用多限于骨髓。外周血样本具有取材方便、相对无创、信息量大的优势，且最近多项临床诊疗指南共识的更新均涉及MFC检测外周血免疫表型的应用。然而，国内目前对MFC检测外周血样本肿瘤细胞和肿瘤前驱病变的认识及应用尚有不足。为进一步了解MFC外周血免疫表型分析在淋巴造血系统肿瘤诊断与随访中应用价值、最新进展和注意事项，促进MFC外周血免疫表型分析的临床应用，制定适用于各类医疗机构的临床实验室、第三方医学检验实验室等相关单位的规范化参考文件，由执笔专家起草初稿，中华医学会检验医学分会临床血液体液学组组织来自全国38家医疗机构的45位专家结合实践经验，并参考了大量文献，经过函审、讨论、调查问卷反馈，最终形成了包括17项内容的本共识。

abstractsMulti-parameter flow cytometry(MFC) plays a crucial role in the detection of haematolymphoid tumors, but it′s application has long been limited to bone marrow. Peripheral blood samples have the advantages of convenient sampling, relatively non-invasive, and large information content. Recent updates of clinical diagnostic and treatment guidelines and consensus have all involved the application of MFC to detect immunophenotyping in peripheral blood. However, there is currently insufficient understanding and application of MFC detection of tumor cells and precursor lesions in peripheral blood samples in China. To further understand the value, latest progress, and precautions of MFC peripheral blood immunophenotyping in the diagnosis and follow-up of haematolymphoid tumors, promote the clinical application of MFC in peripheral blood analysis, and establish standardized reference documents suitable for various medical institutions, including clinical laboratories and third-party medical testing laboratories, this consensus was drafted by leader experts, and reviewed by the Chinese Society of Laboratory Medicine, Clinical Blood and Body Fluids Workgroup organized 45 experts from 38 medical institutions across the country with their practical experience and extensive literatures. After a round of correspondence review, discussion, and questionnaire feedback, the final consensus was formed, including 17 items of content.